Trial Profile

Phase 1c/2a clinical trial of XW003 (Ecnoglutide) in overweight or obese Chinese adult volunteers

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ecnoglutide (Primary)
Indications Obesity
Focus Therapeutic Use

Most Recent Events

23 Jun 2023 According to a Sciwind Biosciences media release, highlight of clinical data for Ecnoglutide (XW003) from this clinical study will be presented at the American Diabetes Association (ADA) 83rd Annual Conference. The ADA conference is being held in San Diego, CA, June 23-26, 2023.
08 Aug 2022 According to Sciwind Biosciences media release, the company plan to discuss these results with the Chinese regulatory authorities and, pending the outcome of such discussions, initiate the pivotal clinical trial for obesity in the near future.
08 Aug 2022 Positive interim results published in the Sciwind Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com